Skip to main content
Menu
ABOUT US
COMPANY OVERVIEW
EXECUTIVE TEAM
SENIOR LEADERSHIP TEAM
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARDS
PARTNERSHIPS
PIPELINE
OUR PIPELINE
Pemvidutide
INVESTORS
OVERVIEW
PRESS RELEASES
PRESS RELEASES
PHARMATHENE, INC. HISTORICAL PRESS RELEASES
IN THE NEWS
EVENTS AND PRESENTATIONS
STOCK INFORMATION
STOCK QUOTE & CHART
HISTORICAL PRICE LOOKUP
INVESTMENT CALCULATOR
ANALYST COVERAGE
GOVERNANCE
DOCUMENTS & CHARTERS
MANAGEMENT TEAM
BOARD OF DIRECTORS
COMMITTEE COMPOSITION
FINANCIALS
SEC FILINGS
INVESTOR RESOURCES
INVESTOR FAQS
IR CONTACT
EMAIL ALERTS
CLINICAL TRIALS
OVERVIEW
EXPANDED ACCESS POLICY
CAREERS
CONTACT US
PIPELINE
Obesity & MASH
Product Name
Preclinical
Phase 1
Phase 2
Phase 3
Status
1
Preclinical
Phase 1
Phase 2
Phase 3
Pemvidutide
(ALT-801)
Obesity
42
%
Status
1
End of Phase 2 FDA Meeting November 2024
Pemvidutide
(ALT-801)
MASH
55
%
Status
1
IMPACT Phase 2b MASH trial top line data in Q2 2025
1
Expected Dates
ABOUT US
COMPANY OVERVIEW
EXECUTIVE TEAM
SENIOR LEADERSHIP TEAM
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARDS
PARTNERSHIPS
PIPELINE
OUR PIPELINE
Pemvidutide
INVESTORS
OVERVIEW
PRESS RELEASES
PRESS RELEASES
PHARMATHENE, INC. HISTORICAL PRESS RELEASES
IN THE NEWS
EVENTS AND PRESENTATIONS
STOCK INFORMATION
STOCK QUOTE & CHART
HISTORICAL PRICE LOOKUP
INVESTMENT CALCULATOR
ANALYST COVERAGE
GOVERNANCE
DOCUMENTS & CHARTERS
MANAGEMENT TEAM
BOARD OF DIRECTORS
COMMITTEE COMPOSITION
FINANCIALS
SEC FILINGS
INVESTOR RESOURCES
INVESTOR FAQS
IR CONTACT
EMAIL ALERTS
CLINICAL TRIALS
OVERVIEW
EXPANDED ACCESS POLICY
CAREERS
CONTACT US
Close Menu